Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results

Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results


­ - Collaboration agreement signed with AstraZeneca: Transgene to build five Invir.IO® oncolytic viruses, each under an option and license agreement
­ - First efficacy results of the combination trial of TG4001 to be presented at ESMO on September 30, 2019
­ - First efficacy results of the combination trial of TG4010 expected in December 2019
­ - Two clinical trials with TG4050 to start in 4Q 2019, in collaboration with NEC
­ - First patient to be enrolled in a new trial with TG6002 in 4Q 2019
­ - Pexa-Vec: decision to stop development in hepatocellular carcinoma
­ - Financial visibility until 2022, following €48.7 million rights issue

Conference call scheduled today at 6:30 p.m. CET (in English)

.../...